# Renal cell carcinoma treatment

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/renal-cell-carcinoma-treatment/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers represents a comprehensive exploration of advancements in the research and treatment of renal cell carcinoma, including studies on various treatment modalities, prognostic factors, molecular characterization, nephron-sparing surgery, immunotherapy, genetic mutations, and clinical guidelines. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10449 |
| Works | 415 |

## Topic papers all

Showing 15 of 415.

- [Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review](https://scholariq.org/papers/adverse-renal-effects-of-immune-checkpoint-inhibitors-a-narrative-review/)
- [Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma/)
- [Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma/)
- [Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial](https://scholariq.org/papers/atezolizumab-in-patients-with-locally-advanced-and-metastatic-urothelial/)
- [Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/temsirolimus-interferon-alfa-or-both-for-advanced-renal-cell-carcinoma/)
- [Everolimus for Advanced Pancreatic Neuroendocrine Tumors](https://scholariq.org/papers/everolimus-for-advanced-pancreatic-neuroendocrine-tumors/)
- [A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer](https://scholariq.org/papers/a-randomized-trial-of-bevacizumab-an-anti-vascular-endothelial-growth-factor/)
- [Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/avelumab-plus-axitinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Distant metastasis occurs late during the genetic evolution of pancreatic cancer](https://scholariq.org/papers/distant-metastasis-occurs-late-during-the-genetic-evolution-of-pancreatic-cancer/)
- [Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study](https://scholariq.org/papers/prognostic-factors-for-overall-survival-in-patients-with-metastatic-renal-cell/)
- [Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma](https://scholariq.org/papers/pazopanib-versus-sunitinib-in-metastatic-renal-cell-carcinoma/)
- [Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carcinoma/)
- [Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-cabozantinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer](https://scholariq.org/papers/nephrectomy-followed-by-interferon-alfa-2b-compared-with-interferon-alfa-2b/)
- [Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis](https://scholariq.org/papers/kidney-organoids-from-human-ips-cells-contain-multiple-lineages-and-model-human/)

## Topic primary papers

Showing 15 of 184.

- [Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma/)
- [Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma/)
- [Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/temsirolimus-interferon-alfa-or-both-for-advanced-renal-cell-carcinoma/)
- [A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer](https://scholariq.org/papers/a-randomized-trial-of-bevacizumab-an-anti-vascular-endothelial-growth-factor/)
- [Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/avelumab-plus-axitinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study](https://scholariq.org/papers/prognostic-factors-for-overall-survival-in-patients-with-metastatic-renal-cell/)
- [Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma](https://scholariq.org/papers/pazopanib-versus-sunitinib-in-metastatic-renal-cell-carcinoma/)
- [Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carcinoma/)
- [Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-cabozantinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer](https://scholariq.org/papers/nephrectomy-followed-by-interferon-alfa-2b-compared-with-interferon-alfa-2b/)
- [Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma](https://scholariq.org/papers/clinical-activity-and-molecular-correlates-of-response-to-atezolizumab-alone-or/)
- [Comparison of 1,800 Laparoscopic and Open Partial Nephrectomies for Single Renal Tumors](https://scholariq.org/papers/comparison-of-1-800-laparoscopic-and-open-partial-nephrectomies-for-single-renal/)
- [An Outcome Prediction Model for Patients with Clear Cell Renal Cell Carcinoma Treated with Radical Nephrectomy Based on Tumor Stage, Size, Grade and Necrosis: The Ssign Score](https://scholariq.org/papers/an-outcome-prediction-model-for-patients-with-clear-cell-renal-cell-carcinoma/)
- [Comparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma](https://scholariq.org/papers/comparisons-of-outcome-and-prognostic-features-among-histologic-subtypes-of/)
- [Solid Renal Tumors: An Analysis of Pathological Features Related to Tumor Size](https://scholariq.org/papers/solid-renal-tumors-an-analysis-of-pathological-features-related-to-tumor-size/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.